Schaufler, Diana
Ast, David F. http://orcid.org/0000-0001-6699-0754
Tumbrink, Hannah L.
Abedpour, Nima
Maas, Lukas
Schwäbe, Ayla E. http://orcid.org/0000-0002-9435-9000
Spille, Inga
Lennartz, Stefanie
Fassunke, Jana
Aldea, Mihaela
Besse, Benjamin
Planchard, David
Nogova, Lucia
Michels, Sebastian
Kobe, Carsten http://orcid.org/0000-0002-2909-0826
Persigehl, Thorsten
Westphal, Theresa
Koleczko, Sophia
Fischer, Rieke
Weber, Jan-Phillip
Altmüller, Janine
Thomas, Roman K.
Merkelbach-Bruse, Sabine
Gautschi, Oliver
Mezquita, Laura
Büttner, Reinhard http://orcid.org/0000-0001-8806-4786
Wolf, Jürgen
Peifer, Martin http://orcid.org/0000-0002-5243-5503
Brägelmann, Johannes http://orcid.org/0000-0002-1306-2169
Scheffler, Matthias http://orcid.org/0000-0002-9031-1368
Sos, Martin L. http://orcid.org/0000-0002-2868-100X
Article History
Received: 25 February 2021
Accepted: 16 November 2021
First Online: 17 December 2021
Competing interests
: D.S. has received honoraria for advisory roles or lectures from BMS, Boehringer-Ingelheim, MSD, Novartis, Roche, Healthcare Consulting Cologne, Abbvie; and has received travel and accommodation support from AstraZeneca, BMS, Boehringer-Ingelheim, MSD, Novartis, Roche, Abbvie. J.F. has received honoraria from AstraZeneca. B.B. has received sponsored research at Gustave Roussy Cancer Center from Abbvie, Amgen, AstraZeneca, BioGen, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Ignyta, IPSEN, Inivata, Janssen, Merck KGaA, MSD, Nektar, Onxeo, OSE immunotherapeutics, Pfizer, Pharma Mar, Roche-Genentech, Sanofi, Servier, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma, Tolero Pharmaceuticals. D.P. has had consulting or advisory roles for AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche, Samsung Bioepis; and has received honoraria from AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche, Samsung Bioepis; and has done clinical trials research as principal or co-investigator (institutional financial interests) with support from AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmun, Sanofi-Aventis, Taiho Pharma, Novocure, Inivata, Takeda, Pharma Mar, Janssen, Daiichi Sankyo; and has received travel and accommodation support from AstraZeneca, Roche, Novartis, Pfizer. L.N. has received honoraria from Pfizer, Celgene, Novartis, Roche, Boehringer Ingelheim, Janssen, BMS, Takeda, Bayer; and has had consulting or advisory roles for Novartis, Boehringer Ingelheim, BMS, Roche, Janssen, Pfizer, Takeda, Bayer; and has received research funding from Pfizer, Novartis, MSD, Janssen, Amgen; and has received travel and accommodation support from Novartis, Pfizer, Celgene, Boehringer Ingelheim, Janssen. S.M. has received honoraria from Pfizer, Novartis, AstraZeneca; and has received research support from Novartis, Pfizer, BMS, Janssen. R.K.T. is the founder/shareholder and has had a consultancy/advisory role of/for PearlRiver Bio GmbH; is the founder/shareholder and has had a consultancy/advisory role of/for Epiphanes Inc; and is the founder/shareholder and has had a consultancy/advisory role of/for CDL Therapeutics GmbH; and has a stock or other ownership and has had a consultancy/advisory role of/for Merck, J&J, AstraZeneca, Bayer; and has a stock or other ownership and has had a consultancy/advisory role of/for Roche; and has a commercial research grant from Roche; and has a stock or other ownership of Novartis, GSK; and has had a consultancy/advisory role for New Oncology AG, Clovis, Daiichi-Sankyo, Boehringer Ingelheim, MSD, Lilly, Sanofi-Aventis, Puma. S.M.-B. has received honoraria for advisory boards or lectures from BMS, Novartis, Roche, Pfizer, Bayer, Molecular Health, Targos, Astra Zeneca; and has received non-financial support from BMS, Janssen. O.G. has received honoraria for advisory boards from AMGEN, LILLY, BAYER. L.M. has had consulting or advisory roles for Roche Diagnostics, Takeda, Roche; and has had a lecture or educational activities for BMS, Tecnofarma, Roche; and has received travel and accommodation support from BMS, Roche; and has received Mentorship program with key opinion leaders from AstraZeneca; and has received sponsored research from Amgen, BMS, Boehringer Ingelheim. T.W. has had an advisory role for Lilly; and has received speakers honoraria from Novartis; and has received travel support from Roche, Pfizer. R.B. is co-founder and chief scientific officer of Targos Mol Inc., Kassel Germany; and has received personal fees and others for advisory boards or lectures from BMS, MSD, Novartis, Roche, Lilly, AstraZeneca, Illumina, AbbVie, Amgen, Boehringer-Ingelheim, Merk-Serono, Qiagen, Pfizer. J.W. has received honoraria for advisory roles or lectures from Amgen, AstraZeneca, Blueprint, BMS, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Ignyta, Janssen, Lilly, Loxo, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda; and has received research support from BMS, Janssen Pharmaceutica, Novartis, Pfizer. M.S. has received honoraria for advisory roles from Pfizer, Roche, AMGEN, Novartis, Takeda, Boehringer Ingelheim; and has received institutional research support from AMGEN, Dracen Pharmaceuticals. M.L.S. is a founder, shareholder and advisor of PearlRiver Bio – a Centessa Pharmaceuticals company - and MLS has a commercial research grant from PearlRiver Bio - a Centessa company. The remaining authors declare no competing interests.